{"id":2355,"date":"2025-01-08T17:41:32","date_gmt":"2025-01-08T14:41:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2355"},"modified":"2025-03-07T15:26:36","modified_gmt":"2025-03-07T12:26:36","slug":"avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization\/","title":{"rendered":"Avidity Biosciences se prepara para a submiss\u00e3o e comercializa\u00e7\u00e3o do BLA 2025 de tr\u00eas programas de doen\u00e7as musculares raras"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Uma empresa biofarmac\u00eautica dedicada ao desenvolvimento de uma nova classe de tratamentos de RNA conhecidos como Conjugados de Anticorpos Oligonucleot\u00eddeos (AOCsTM), a Avidity Biosciences, Inc., relatou hoje seus avan\u00e7os e planos para um ano revolucion\u00e1rio em 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Esses marcos esperados significativos incluem a conclus\u00e3o de tr\u00eas programas potencialmente registracionais, o envio de um Pedido de Licen\u00e7a Biol\u00f3gica (BLA) para delpacibart zotadirsen (del-zota) para indiv\u00edduos com muta\u00e7\u00f5es de distrofia muscular de Duchenne pass\u00edveis de salto do exon 44 (DMD44), a prepara\u00e7\u00e3o para v\u00e1rios lan\u00e7amentos de produtos em DMD44, distrofia miot\u00f4nica tipo 1 (DM1) e distrofia muscular facioescapulohumeral (FSHD) e o estabelecimento de um neg\u00f3cio internacional completamente integrado para dar suporte a um pipeline AOC em expans\u00e3o em cardiologia de precis\u00e3o e doen\u00e7as neuromusculares.<\/p>","protected":false},"excerpt":{"rendered":"<p>A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,128,130,129,66,77],"class_list":["post-2355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-bla","tag-dm1","tag-dmd44","tag-duchenne-muscular-dystrophy","tag-exon-skipping"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=2355"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/2357"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=2355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=2355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=2355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}